• Bioasis Technologies (TSX.V: BTI) (OTCQB: BIOAF) CEO, Deborah Rathjen on the blood-brain barrier (Ep 44)

  • Jul 9 2021
  • Length: 17 mins
  • Podcast

Bioasis Technologies (TSX.V: BTI) (OTCQB: BIOAF) CEO, Deborah Rathjen on the blood-brain barrier (Ep 44) By cover art

Bioasis Technologies (TSX.V: BTI) (OTCQB: BIOAF) CEO, Deborah Rathjen on the blood-brain barrier (Ep 44)

Listen for free

View show details

  • Summary

  • Deborah Rathjen, CEO of Bioasis Technologies (BTI.V) talks about the company's ground-breaking xB3 platform which allows therapeutic drugs to pass through the seemingly impenetrable blood-brain barrier, providing an effective treatment methodology for such neurological disorders as Alzheimer's disease, Lewy Body Dementia and Parkinson's. In short, Bioasis' final frontier solution could very well revolutionize medical science, potentially helping to heal the one billion people suffering from neurological disorders worldwide. Tune in!
    Show more Show less
activate_primeday_promo_in_buybox_DT
Economics Personal Finance
Show more Show less

What listeners say about Bioasis Technologies (TSX.V: BTI) (OTCQB: BIOAF) CEO, Deborah Rathjen on the blood-brain barrier (Ep 44)

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available